A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers

Foot Ulcer Clinical Trial

Official title:

An Exploratory, Double-Blind, Randomized, Placebo Controlled Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00069446
• Other study ID #: VGF2763g
• Status: Completed
• Phase: Phase 1
• First received: September 25, 2003
• Last updated: May 9, 2017
• Start date: August 2003
• Est. completion date: October 2004

Study information

• Verified date: May 2017
• Source: Genentech, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase I, double blind, randomized, placebo-controlled study that will enroll approximately 50 adult subjects with Type 1 or Type 2 diabetes mellitus and chronic, diabetic foot ulcers. The study will be conducted at approximately 12 investigational sites in the United States.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: October 2004
• Est. primary completion date: October 2004
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Signed Informed Consent

• 18-80 years old

• For females of childbearing potential, use of an effective method of contraception:

abstinence; surgical sterilization; oral contraceptives; barrier contraception with either a condom, sponge, or diaphragm in conjunction with spermicidal gel; an intrauterine device (IUD); or contraceptive hormone implant or patch

• Type 1 or 2 diabetes mellitus

• Single, full-thickness (i.e., extending into the subcutaneous tissue or beyond) ulcer of the foot below the malleolus that does not involve bone, tendons, ligaments, or muscle

• Chronic ulcer with a duration of = 4 weeks but < 6 months

• Ulcer area with sharp debridement of = 1.0 cm^2 and = 4.0 cm^2

• Ankle-brachial index (ABI) of = 0.6 and = 1.2 on the study foot

• Glycosylated hemoglobin A1c (HbA1c) of = 12%

Exclusion Criteria:

• History of neoplasia or current neoplasia (with the exception of non-melanoma skin cancer)

• Proliferative diabetic retinopathy or wet age-related macular degeneration

• Active ulcer infection or cellulitis of any ulcer

• Ulcers with an etiology not related to diabetes (e.g., thermal, chemical, radiation insult)

• Connective tissue disease

• Active osteomyelitis of the study foot

• Subjects with ulcers related to an incompletely healed amputation wound

• Subjects with Charcot or other deformity of the study foot involving the study ulcer

• Immunosuppressive treatment, including radiation therapy, non-inhaled corticosteroids (inhaled corticosteroid = 1000 ug daily dose is acceptable), and chemotherapy

• Pregnancy or lactation

• Multiple ulcers in the study foot

• Renal failure (serum creatinine of >3.0 mg/dL)

• Poor nutritional status (albumin of <3.0 g/dL)

• Known hypersensitivity to any ingredients of telbermin, placebo, or vehicle, including excipients in the formulation of telbermin or placebo gel (trehalose dihydrate, polysorbate 20, succinic acetic acid, succinic acetic acid disodium, and hexahydrate)

• Known prior inability to complete required study visits during treatment period

• Use of any other investigational drug or therapy on the study foot within the past month

• Previous use of a platelet-derived or other growth factors on the study ulcer within the past 3 months

Related Conditions & MeSH terms

• Diabetic Foot
• Foot Ulcer
• Ulcer

Intervention

Drug:
• rhuMAb VEGF (telbermin)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Genentech, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of clinically significant hypotension.
Secondary	Incidence of clinically significant ulcer infection defined by increased discharge and malodorous exudates from the ulcer, fever, and a white blood cell (WBC) count of >10,000/uL
Secondary	Development of anti telbermin antibodies
Secondary	Incidence of adverse events
Secondary	Percent reduction in total ulcer surface area.